60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given Neutral Rating at HC Wainwright

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “neutral” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Saturday, March 22nd.

60 Degrees Pharmaceuticals Stock Down 3.2 %

SXTP stock opened at $1.82 on Friday. The firm has a market cap of $2.68 million, a PE ratio of -0.18 and a beta of 4.52. The business has a 50 day moving average of $2.65 and a 200-day moving average of $4.67. 60 Degrees Pharmaceuticals has a 12-month low of $1.41 and a 12-month high of $35.99.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.